Highest-materiality recent filing
Relay Therapeutics prices $316M public offering; underwriters exercise overallotment
Entered underwriting agreement for 22,916,667 shares at $12.00/sh; full exercise of 3,437,500 overallotment option.
60% of 20 evaluable patients achieved a volumetric response by BICR at first MRI in Phase 2 ReInspire trial; 95% experienced lesion reduction.
Relay Therapeutics Q1 2026 net loss $73.3M; FDA BTD for zovegalisib; cash $642M
FDA granted Breakthrough Therapy designation to zovegalisib+fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer.
Relay Therapeutics reports 44% ORR for zovegalisib triplet; plans Phase 3 in frontline breast cancer
ORR of 44% (15/34) in heavily pre-treated, CDK4/6-experienced patients; 85% tumor reduction.
Relay Therapeutics reports zovegalisib + fulvestrant Phase 1/2 data: 11.1 mo median PFS at RP3D
Median PFS of 11.1 months (95% CI 7.3-13.0) in 57 evaluable PI3Kα-mutated HR+/HER2- mBC patients.
Relay Therapeutics reports Q4 net loss $0.32/share; cash $554.5M; zovegalisib milestones in 2026
Q4 2025 net loss $54.9M ($0.32/share) vs $76.0M ($0.45) in Q4 2024; full year net loss $276.5M ($1.61/share).
Relay's zovegalisib granted FDA Breakthrough Therapy Designation for PIK3CA-mutant breast cancer
FDA granted Breakthrough Therapy Designation to zovegalisib + fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6i.
Relay Therapeutics Q3 net loss $74.1M, cash $596.4M; appoints two directors
Net loss $74.1M ($0.43 per share) vs $88.1M ($0.63) in Q3 2024.
Relay Therapeutics Q2 net loss narrows to $70.4M; initiates Phase 3 ReDiscover-2 trial
Net loss of $70.4M ($0.41 per share) vs $92.2M ($0.69) in Q2 2024.
Relay Therapeutics terminates Binney St lease early, signs Kendall Square lease; saves ~$16M in rent
Paid $2.5M modification fee and transferred FF&E to landlord to terminate Binney St lease early.
Relay Therapeutics Q1 net loss $77M; cash runway into 2029, RLY-2608 Phase 3 on track
Net loss $77.1M ($0.46/share) vs $81.4M ($0.62/share) in Q1 2024; revenue $7.7M from Elevar license completion.
Relay Therapeutics Q4 net loss $0.45/sh; cash $781M; Phase 3 ReDiscover-2 trial mid-2025
Net loss of $76.0M ($0.45/sh) in Q4 2024 vs $83.5M ($0.67/sh) in Q4 2023.
Median PFS 9.2 months overall, 11.4 months in 2L patients at RP2D (600mg BID) without PTEN/AKT co-mutations.
Relay Therapeutics reports Q3 2024 net loss $88.1M; RLY-2608 shows 9.2-month median PFS
Net loss $88.1M ($0.63/share); revenue $0 vs $25.2M year ago (prior Genentech milestone).
Relay Therapeutics prices $200M public offering of common stock at $7.00/share
Public offering of 28.57M shares at $7.00/share; gross proceeds ~$200M.
Relay reports positive interim RLY-2608 data: 9.2mo PFS in PI3Kα-mutated breast cancer
Median PFS 9.2 months (all mutations) and 10.3 months (kinase mutations) at RP2D in heavily pre-treated patients without PTEN/AKT co-mutations.
Relay Therapeutics Q2 net loss $0.69/sh; cash $688M; new preclinical programs unveiled
Q2 net loss $92.2M ($0.69/share) vs $98.5M ($0.81) in Q2 2023.
Genentech terminates migoprotafib collaboration; Relay loses future milestones
Genentech terminated without cause; effective 180 days after July 11, 2024.
Relay Therapeutics announces Pfizer collaboration and three new pipeline programs
Clinical collaboration with Pfizer to evaluate RLY-2608 + atirmociclib + fulvestrant in PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024.
Relay Therapeutics Q4 2023 net loss $83.5M; cash $750M funds into H2 2026
Net loss $83.5M in Q4 2023 ($0.67 per share) vs $67.5M loss in Q4 2022.
Net loss of $65.7M ($0.54/share) vs $84.2M loss ($0.76) in Q3 2022; revenue $25.2M from Genentech milestone.
Relay Therapeutics reports RLY-4008 data: 35% ORR in FGFR2 fusions; cash runway extended to 2H2026
RLY-4008 achieved 35% ORR in FGFR2-fusion tumors (n=26) and 40% ORR in HR+/HER2- breast cancer (n=10); durable responses of ≥6 months in most responders.
Relay Therapeutics Q2 net loss $98.5M; RLY-2608 dose expansion initiated with 86% CBR
Net loss of $98.5M ($0.81/share) in Q2 2023, up from $76.8M loss ($0.71) in Q2 2022; R&D expenses rose to $88.2M.
Relay reports complete dose escalation data for RLY-4008; 73% ORR in FGFRi-naïve CCA at pivotal dose
Among FGFRi-naïve FGFR2-fusion CCA patients at or above 70mg QD (n=11): 73% ORR, median DoR 11.2 months.
Relay Therapeutics Q1 net loss $94.2M; cash $937.8M; RLY-2608 shows no Grade 3 hyperglycemia
Net loss of $94.2M ($0.78 per share) vs $62.0M ($0.57) in Q1 2022; R&D expense $82.8M up from $51.7M.
No Grade 3 hyperglycemia, rash, or diarrhea at target exposures; no dose-limiting toxicities or discontinuations.
Relay Therapeutics reports Q4 2022 net loss of $67.5M; cash ~$1B funds into 2025
Net loss per share $0.56 for Q4 2022, flat vs Q4 2021; full-year net loss $290.5M ($2.59/share).
Relay Therapeutics Q3 net loss $84.2M ($0.76/sh); RLY-4008 88% ORR in FGFR2-fusion CCA
Net loss $84.2M vs $60.8M YoY; R&D expenses rose to $66.9M from $45.0M.
Relay Therapeutics prices $300M public offering of 11.32M shares at $26.50 per share
Priced public offering of 11,320,755 shares at $26.50/share; gross proceeds ~$300M.
Relay Therapeutics reports 88% interim ORR for RLY-4008 in FGFR2-fusion CCA at pivotal dose
15 of 17 efficacy-evaluable patients at 70 mg QD achieved partial response (88% interim ORR); 14 confirmed, 1 unconfirmed.
Relay Therapeutics reports 88% ORR at RP2D for RLY-4008 in FGFR2 fusion CCA
At RP2D (70 mg QD), ORR 88% (15/17), confirmed ORR 82.4% (14/17), disease control rate 100%.
Relay Therapeutics Q2 2022 net loss $76.8M; pipeline progress, new board member
Net loss $76.8M ($0.71/share) in Q2 2022 vs $193.4M ($2.10) in Q2 2021; prior year included $134.9M ZebiAI acquisition costs.
Relay Therapeutics announces FDA alignment on RLY-4008 accelerated path; 62% response rate in CCA
FDA aligned on single-arm trial design for RLY-4008 at 70mg QD to potentially support accelerated approval in FGFRi-naïve FGFR2-fusion CCA.
Relay Therapeutics reports FY2021 net loss of $363.9M; cash $958M into 2025
Q4 net loss $67.5M vs net income $35.3M in Q4 2020; full-year net loss $363.9M ($3.82 loss per share).
Relay Therapeutics Q3 net loss $60.8M; cash + offering totals ~$1B, runway into 2025
Net loss $60.8M ($0.66/share) vs $36.1M ($3.00/share) Q3 2020; R&D expenses nearly doubled to $45.0M.
On June 9, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Claire Mazumdar, Ph.D., MBA as a member of the Board, effective as of June 9, 2025.
On July 25, 2022, the board of directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Sekar Kathiresan, M.D. to the Board as a class III director to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.
On and effective as of December 8, 2021, Dipchand (Deep) Nishar tendered his resignation as a Class III director of the board of directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”).
Max materiality 0.85 · Median 0.65 · Most common event other_material